Literature DB >> 30019249

Study design of multi-center, open-label randomized controlled, head-to-head trial comparing minodronic acid and raloxifene: Japanese Osteoporosis Intervention Trial (JOINT)-04.

Yukari Uemura1, Shiro Tanaka2, Teruhiko Miyazaki3, Mayumi Tsukiyama3, Teruki Sone4, Akira Taguchi5,6, Satoshi Soen7, Satoshi Mori8, Hiroshi Hagino9, Toshitsugu Sugimoto10, Masao Fukunaga11, Hiroaki Ohta12, Toshitaka Nakamura13, Hajime Orimo13, Masataka Shiraki14.   

Abstract

We planned to conduct multi-center, open-labeled, blinded-endpoints, head-to-head randomized trial of minodronate and raloxifene to compare incidences of vertebral and non-vertebral fractures. The study is the Japanese Osteoporosis Intervention Trial protocol number 4 (JOINT-4). Here, we present the pre-fixed study design. The inclusion criteria are ambulatory older women with osteoporosis, aged > 60 years, and without pre-specified risk factors for secondary osteoporosis and dementia. The subjects who meet selection criteria will be randomly allocated to the raloxifene (60 mg/day) or minodronate (1 mg/day or 50 mg/4 weeks) groups using the central registry. The co-primary endpoints are osteoporotic (vertebral, humeral, femoral, and radial), vertebral, and major osteoporotic (clinical vertebral, humeral, femoral, and radial) fractures. Furthermore, we plan to use the Hochberg procedure to preserve an overall type 1 error rate. In addition, changes in bone mineral density (BMD), hip-structure analysis (HSA) variables, height, bone turnover markers, serum cholesterol and triglyceride concentrations, dental health questionnaire, fall frequency, fall risk index, nursing care level, physical function, quality of life (QOL), and safety profiles were assessed as secondary endpoints. To detect 24% reduction of major osteoporotic fractures with 80% power and a two-sided significance level of 5% with a 2-year observation period, 1734 patients/treatment arm would be required. Subgroup analysis stratified to the following factors age, body mass index, BMD, 25-hydroxyvitamin D concentration, estimated glomerular filtration rate (eGFR), prevalent vertebral fracture number, hypertension status, and diabetes mellitus is pre-specified. The protocol is registered in the trial registry system, and the trial identification number is UMIN000005433.

Entities:  

Keywords:  Fractures; Head-to-head randomized trial; Minodronate; Osteoporotic; Raloxifene

Mesh:

Substances:

Year:  2018        PMID: 30019249     DOI: 10.1007/s00774-018-0942-z

Source DB:  PubMed          Journal:  J Bone Miner Metab        ISSN: 0914-8779            Impact factor:   2.626


  3 in total

1.  Incidence of osteonecrosis of the jaw in Japanese osteoporosis patients taking minodronic acid.

Authors:  Akira Taguchi; Yukari Uemura; Takumi Imai; Shiro Tanaka; Hiroaki Ohta; Toshitaka Nakamura; Hajime Orimo; Toshitsugu Sugimoto; Satoshi Soen; Masataka Shiraki
Journal:  J Bone Miner Metab       Date:  2019-02-04       Impact factor: 2.626

2.  Risk factors for incident vertebral fractures in osteoporosis pharmacotherapy: a 2-year, prospective, observational study.

Authors:  Hiroshi Hagino; Yukari Uemura; Satoshi Mori; Teruki Sone; Hiroaki Ohta; Toshitaka Nakamura
Journal:  J Bone Miner Metab       Date:  2021-03-18       Impact factor: 2.626

3.  Influence of symptomatic periodontal disease on changes in skeletal bone density during medication therapy for osteoporosis in postmenopausal women: the Japanese Osteoporosis Intervention Trial (JOINT)-04 and JOINT-05.

Authors:  Akira Taguchi; Yukari Uemura; Shiro Tanaka; Hiroaki Ohta; Satoshi Mori; Hiroshi Hagino; Masataka Shiraki; Toshitaka Nakamura; Satoshi Soen
Journal:  Arch Osteoporos       Date:  2021-12-27       Impact factor: 2.617

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.